Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Depreciation and Depletion (2017 - 2018)

Denali Therapeutics (DNLI) has disclosed Depreciation and Depletion for 2 consecutive years, with $2.3 million as the latest value for Q3 2018.